Morgan Stanley boosted its position in Cardiovascular Systems Inc (NASDAQ:CSII) by 53.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 221,098 shares of the medical device company’s stock after acquiring an additional 77,458 shares during the quarter. Morgan Stanley owned 0.64% of Cardiovascular Systems worth $8,654,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. TIAA CREF Investment Management LLC lifted its holdings in Cardiovascular Systems by 110.6% in the third quarter. TIAA CREF Investment Management LLC now owns 284,507 shares of the medical device company’s stock worth $11,136,000 after buying an additional 149,422 shares during the period. Teachers Advisors LLC lifted its holdings in Cardiovascular Systems by 420.6% in the third quarter. Teachers Advisors LLC now owns 317,801 shares of the medical device company’s stock worth $12,439,000 after buying an additional 256,759 shares during the period. AQR Capital Management LLC lifted its holdings in Cardiovascular Systems by 45.3% in the third quarter. AQR Capital Management LLC now owns 76,519 shares of the medical device company’s stock worth $2,995,000 after buying an additional 23,864 shares during the period. MetLife Investment Advisors LLC lifted its holdings in Cardiovascular Systems by 60.1% in the third quarter. MetLife Investment Advisors LLC now owns 23,939 shares of the medical device company’s stock worth $937,000 after buying an additional 8,988 shares during the period. Finally, Castleark Management LLC purchased a new stake in Cardiovascular Systems in the third quarter worth about $6,733,000. 79.66% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have commented on CSII shares. Needham & Company LLC restated a “hold” rating on shares of Cardiovascular Systems in a report on Wednesday, October 31st. Zacks Investment Research restated a “hold” rating on shares of Cardiovascular Systems in a report on Monday, November 12th. Finally, BidaskClub upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a report on Tuesday, January 22nd. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $47.50.
Shares of CSII opened at $33.36 on Tuesday. The company has a quick ratio of 3.88, a current ratio of 4.38 and a debt-to-equity ratio of 0.15. Cardiovascular Systems Inc has a one year low of $20.58 and a one year high of $40.00. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of 667.20 and a beta of 2.09.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings data on Wednesday, January 30th. The medical device company reported $0.01 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $0.05. Cardiovascular Systems had a net margin of 0.74% and a return on equity of 1.28%. The business had revenue of $60.21 million during the quarter, compared to analyst estimates of $59.66 million. Sell-side analysts predict that Cardiovascular Systems Inc will post -0.06 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Cardiovascular Systems Inc (CSII) Shares Bought by Morgan Stanley” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2019/02/12/cardiovascular-systems-inc-csii-shares-bought-by-morgan-stanley.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.